Practolol and the safety of other beta blockers

Abstract

Recognition of the "occulomucocutaneous syndrome" related to practolol administration has caused the safety of other beta-blocking agents to come under close scrutiny. No satisfactory means of screening for at-risk patients is available. ANF estimation, has considerable limitations as both a screening and a diagnostic procedure. Patients with skin lesions alone may not be positive, while even advanced cases often show very low titres. There are important technical difficulties with the assay and interpretation of results is hindered by an increase in incidence of the antibody with age, in females, and in patients on a wide variety of other therapeutic agents.